Clinical Trial: Exploratory Biomarker Study Accompanying an Investigator-Initiated Phase II Trial Evaluating the Efficacy and Safety of the PAI-1 Inhibitor TM5614 in Combination with Chemoradiotherapy Followed by Consolidation Therapy with an Immune Checkpoint Inhibitor for Locally Advanced Non-Small Cell Lung Cancer (Japan)

Tokyo, July 25 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062321) titled 'A study to identify factors associated with the efficacy and adverse effects of treatment combining the PAI-1 inhibitor TM5614 with chemoradiotherapy and immunotherapy for locally advanced non-small cell lung cancer' on July 24.

Study Type: Observational

Primary Sponsor: Institute - Hiroshima University

Condition: Condition - Locally advanced non-small cell lung cancer Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - As an ancillary biomarker study of the investigator-initiated phase II trial entitled, A Phase II Investigator-Initiated Trial Evaluating the Effi...